Celgene’s Abraxane May Add Lung Cancer Use

Celgene’s Abraxane may receive FDA approval for lung cancer by Oct. 12. The company applied for approval of the drug in combination with carboplatin as a treatment for first-line non-small cell lung cancer (NSCLC) patients who are not candidates for potentially curative surgery and/or radiation therapy.

Read more>>

Bloomberg BRIEF Newsletters